Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 29;17(9):1494.
doi: 10.3390/cancers17091494.

Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma

Elliott L Fite  1 , Mina S Makary  2
Affiliations
Review

Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma

Elliott L Fite et al. Cancers (Basel). .

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer deaths worldwide. Despite the high incidence of HCC, mortality remains high, with an estimated 5-year survival rate of less than 20%. Surgical resection represents a potential curative treatment for HCC; however, less than 20% of patients with HCC are candidates for surgical resection. In patients with unresectable HCC, Yttrium-90 (Y90) transarterial radioembolization (TARE) has emerged as an innovative treatment option. This locoregional therapy delivers high doses of radiation directly to liver tumors via intra-arterial injection, allowing for the targeted destruction of malignant cells while sparing surrounding healthy tissue. In this review, we will explore the latest advances in Y90 TARE for the treatment of HCC, focusing on key developments such as the following: (1) improvements in radiation lobectomy and segmentectomy techniques, (2) the introduction of personalized dosimetry, (3) the integration of combination therapies, (4) the use of imageable microspheres, (5) pressure-enabled Y90 delivery systems, and (6) the application of Y90 surrogates.

Keywords: Yttrium-90; hepatocellular carcinoma; transarterial radioembolization.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Y90 TACE procedure. (A) Radiation segmentectomy. (B) Radiation lobectomy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Yu Q., Khanjyan M., Fidelman N., Pillai A. Contemporary Applications of Y90 for the Treatment of Hepatocellular Carcinoma. Hepatol. Commun. 2023;7:e0288. doi: 10.1097/HC9.0000000000000288. - DOI - PMC - PubMed
    1. Zane K.E., Nagib P.B., Jalil S., Mumtaz K., Makary M.S. Emerging Curative-Intent Minimally-Invasive Therapies for Hepatocellular Carcinoma. World J. Hepatol. 2022;14:885–895. doi: 10.4254/wjh.v14.i5.885. - DOI - PMC - PubMed
    1. Jipa A.M., Makary M.S. Locoregional Therapies for Hepatobiliary Tumors: Contemporary Strategies and Novel Applications. Cancers. 2024;16:1271. doi: 10.3390/cancers16071271. - DOI - PMC - PubMed
    1. Fite E.L., Makary M.S. Transarterial Chemoembolization Treatment Paradigms for Hepatocellular Carcinoma. Cancers. 2024;16:2430. doi: 10.3390/cancers16132430. - DOI - PMC - PubMed
    1. Liu Y., Ren Y., Ge S., Xiong B., Zhou G., Feng G., Song S., Zheng C. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis. Front. Oncol. 2021;11:662408. doi: 10.3389/fonc.2021.662408. - DOI - PMC - PubMed

LinkOut - more resources